Obesity

Endoscopic sleeve gastroplasty was more cost-effective and sustained greater weight loss over 5 years compared with semaglutide for patients with class II obesity, according to data published in JAMA Network Open.

Tirzepatide improved obstructive sleep apnea symptoms compared with placebo among adults with obesity, according to results from the SURMOUNT-OSA trials.

Despite similar pain and function scores, patients who were obese and underwent arthroscopic rotator cuff repair had increased rates of complications, readmissions and reoperations vs. non-obese patients, published results showed.

BOSTON — Time-restricted eating did not result in more weight loss vs. a usual eating pattern, suggesting that overall caloric intake may have a larger effect on weight loss than meal timing, researchers reported.

Some changes in gut microbiome composition may increase the risk for obesity, with those changes affecting men and women differently, according to data that will be presented at the European Congress on Obesity.

Hundreds of clinicians will gather in Denver next week to discuss the latest treatment strategies and evidence-based approaches to obesity management.

This year’s ACP Internal Medicine Meeting is taking place in person in Boston and virtually from April 18 to April 20.

Adults with moderate to severe obstructive sleep apnea and obesity had reductions in sleep apnea severity at 1 year with 10 mg or 15 mg of tirzepatide, according to topline results from two phase 3 trials.

Adults with obesity-related heart failure and diabetes saw improvements in heart failure symptoms and physical function with semaglutide 2.4 mg compared with placebo, a recent study showed.

DENVER — In adults with multiple sclerosis, obstructive sleep apnea increases brain atrophy independent of obesity, a common comorbidity, according to a poster at the American Academy of Neurology annual meeting.